This week, Johnson & Johnson reported third quarter earnings that beat Wall
Street analysts’ expectations after already hiking prescription drug prices
more than 30 times so far this year.





 



BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Company Beats Wall Street Expectations Following Price Hikes on
Blockbuster Products



This week, Johnson & Johnson reported third quarter earnings that beat Wall
Street analysts’ expectations after already hiking prescription drug prices
more than 30 times so far this year.



During Johnson & Johnson’s third quarter earnings call
<[link removed]>
, an analyst from Wolfe Research posed a question regarding long term guidance
for the pharmaceutical giant. In response, Chairman and CEO Joaquin Duato
boasted of strong confidence in the company’s financial performance, “I want to
underline this is not only a very strong quarter, it’s also an indication, a
signal that Johnson & Johnson is in an accelerated cycle of growth, which we
expect is going to last the balance of the decade.” Johnson & Johnson is one of
the many pharmaceutical companies that routinely hikes the prices of their
blockbuster drugs, directly contributing to increased sales, revenue and the
company’s overall growth.



Get a full recap of Johnson & Johnson’s Q3 earnings here:



Johnson & Johnson

* Johnson & Johnson reported third quarter earnings
<[link removed]>
that beat Wall Street analysts’ expectations.
* The Big Pharma giant brought in sales of $23.99 billion
<[link removed]>
, beating expectations of $23.76 billion.
* Johnson & Johnson’s pharmaceutical business rose 6.8 percent
<[link removed]>
in the quarter, driven by cancer drugs Darzalex and Carvykti and immunology
treatments Tremfya and Simponi.
* Johnson & Johnson raised its sales outlook for 2025 to between $93.5
billion and $93.9 billion
<[link removed]>
, up from the previous range of $93.2 billion to $93.6 billion.
Johnson & Johnson’s considerable earnings go hand in hand with the steady
pattern of hiking prices on blockbuster drugs.


Johnson & Johnson

* Johnson & Johnson has hiked prices on 31 prescription drugs
<[link removed]> in 2025, including a 5.5
percent increase on multiple myeloma drug Darzalex and a 4.7 percent increase
on psoriasis drug Stelara.
* Johnson & Johnson engaged in 35 price hikes
<[link removed]> in 2024, including a 6.3
percent increase on Darzalex, and five percent increases on Erleada and Stelara.
* According to a December 2024 ICER report
<[link removed]>, price
hikes that were unsupported by new clinical evidence on multiple myeloma drug
Darzalex led to additional consumer spending of$190 million
<[link removed]>.
* Johnson & Johnson also engaged in 36 price hikes
<[link removed]> in 2023, including a 4.5
percent increase on Darzalex, a five percent increases on Erleada and a four
percent increase on Stelara.
* Spending on the company’s blockbuster cancer drug Imbruvica is expected to
exceed $41 billion <[link removed]> between 2027-2036 thanks
to an anti-competitive patent scheme that extended a monopoly on the
high-priced cancer drug by more than nine years. Imbruvica costs an eye-popping
$180,000 per year
<[link removed]>
.
Stay tuned as we continue to monitor third quarter earnings calls from brand
name drug companies in the coming weeks.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>